67% five-year survival rate in glioblastoma therapy, according to CANbridge Pharmaceuticals study
CANbridge Pharmaceuticals Inc. has announced that its therapy for glioblastoma has shown a 67% survival…
March 17, 2023 - 3 minutes
glioblastoma
Enterome completes patient enrollment for recurrent glioblastoma study
Enterome has completed patient enrollment in its phase 2 clinical trial (ROSALIE) evaluating its lead…
December 12, 2022 - 3 minutes
NW Bio reports positive top-line results from phase 3 glioblastoma trial
Northwest Biotherapeutics, which is developing DCVax personalized immune therapies for solid tumor cancers, yesterday (November…
November 18, 2022 - 4 minutes
Healthy volunteer study for tablet to treat brain cancer open for recruitment
A clinical stage drug company developing sulforaphane-based medicines for cancer treatment has started recruiting for…
October 20, 2022 - 4 minutes
License from Helmholtz Munich will enable progression of brain cancer treatment
A treatment for one of the most aggressive and difficult to treat cancers is the…
October 20, 2022 - 3 minutes
